HUMPHREY RACHEL 4

What Happened

• Rachel Humphrey, a director of Pyxis Oncology (PYXS), sold a total of 15,496 shares in open-market transactions in April 2025, generating roughly $15,918 in proceeds. The filings list three sales: 1,400 shares on 2025-04-14 (@ $0.97, $1,362), 200 shares on 2025-04-17 (@ $0.97, $194), and 13,896 shares on 2025-04-21 (weighted avg $1.03, $14,362). These were disposals (sales), not purchases.

Key Details

• Dates and prices: 2025-04-14 — 1,400 sh @ $0.97 (multiple trades; prices reported $0.97–$0.98); 2025-04-17 — 200 sh @ $0.97; 2025-04-21 — 13,896 sh @ weighted avg $1.03 (executed across trades priced $0.97–$1.09).
• Total sold: 15,496 shares for approximately $15,918.
• Shares owned after the transactions: not specified in the provided excerpt of the Form 4.
• Notable footnotes: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Humphrey on December 5, 2024. The filing notes multiple trades and provides weighted-average prices; additional trade-level details are available upon request to the SEC, issuer, or a security holder.
• Timeliness: The Form 4 was filed on 2026-03-25 while the trades occurred in April 2025, indicating a substantial delay between the transactions and the filing.

Context

• These were routine open-market sales executed under a pre-established 10b5-1 plan, which typically allows insiders to sell shares according to a preset schedule and is intended to reduce concerns about trading on material nonpublic information. Sales are generally less informative than purchases about an insider’s view of the company—this report documents disposals, not insider buying.